Key facts
- AbogenBio’s last known valuation is $3.7B (Nov 2021).
- It has raised $1.1B; the latest was Later Stage VC in Jul 2025.
- Notable investors include Coatue Management, SoftBank Investment Advisers, Qiming Venture Partners, Temasek Holdings, Oriental Fortune Capital — 44 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 44 names
- ·Watchlist + deal alerts for AbogenBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AbogenBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AbogenBio
Developer of mRNA based therapeutics focused on advancing clinical stage RNA medicines with a mission to revolutionise the future of health and life. The company's offerings include mRNA LNP platforms, mRNA modified therapeutics, delivery technology systems, immuno oncology candidates, autoimmune disease therapies and infectious disease vaccine programs, enabling the creation of scalable, next generation RNA medicines that expand treatment possibilities across multiple therapeutic areas.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2019
- Employees
- 8
- Website
- abogenbio.com/
- Ownership
- Privately Held (backing)
AbogenBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AbogenBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AbogenBio in its N-PORT filings yet. We sweep new filings monthly.